ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 408,64
-0,30%
Dow Jones
42 180,47
0,58%
DAX
20 132,85
-0,44%
Brent Oil
80,195
-0,52%
Bitcoin
91 824,03
-2,82%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Iovance Biotherapeutics Inc (IOVA) Cours

Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc (IOVA)

NASDAQ
5,98
-0,42
( -6,56% )
Mis à jour : 20:04:07
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
5,98
Prix Achat
5,98
Prix Vente
5,99
Volume échangé
9 424 508
5,91 Fourchette du Jour 6,3499
5,91 Plage de 52 semaines 18,33
Cap du marché
1,823B
Clôture Veille
6,40
Ouverture
6,31
Dernière Transaction
65
@
5.98
Dernière heure de transaction
20:04:12
Volume financier
US$ 56 781 747
VWAP
6,0249
Volume moyen (3 m)
7 252 126
Actions en circulation
304 780 790
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-4,10
Bénéfice par action (BPA)
-1,46
Chiffre d'affairess
1,19M
Bénéfice net
-444,04M

À propos de Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline can... Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. Show more

Secteur
Biological Pds,ex Diagnstics
Industrie
Biological Pds,ex Diagnstics
Site Web
www.iovance.com
Siège social
Camden, Delaware, USA
Fondé
-
Iovance Biotherapeutics Inc est coté dans le secteur Biological Pds,ex Diagnstics de la NASDAQ avec le ticker IOVA. Le dernier cours de clôture d'Iovance Biotherapeutics était de US$6,40. Au cours de la dernière année, les actions de Iovance Biotherapeutics ont été négociées dans une fourchette de prix de US$ 5,91 à US$ 18,33.

Iovance Biotherapeutics compte actuellement 304 780 790 actions en circulation. La capitalisation boursière d'Iovance Biotherapeutics est de US$1,95 milliard. Iovance Biotherapeutics a un ratio cours/bénéfice (ratio PE) de -4.10.

Flux d'options Iovance Biotherapeutics (IOVA)

Voir le flux d'options complet

Flux global

Haussier

Prime nette

486k

Calls / Puts

100,00%

Ach. / Vent.

233,33%

OTM / ITM

1 000,00%

Sweeps Ratio

0,00%

IOVA Dernières nouvelles

Plus de nouvelles

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...

20 Décembre 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

18 Décembre 2024
Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans

13 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 Décembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

04 Décembre 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

02 Décembre 2024
Edgar (US Regulatory)

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

SAN CARLOS, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel...

26 Novembre 2024
GlobeNewswire Inc.

Form 8-K - Current report

21 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-1.73-22.43839169917.717.785.91100587216.90580377CS
4-1.95-24.59016393447.938.155.9179167887.2932442CS
12-4.22-41.372549019610.212.5055.9172521268.83422378CS
26-2.76-31.57894736848.7412.5055.9165887159.28512594CS
52-2.92-32.8089887648.918.335.91717494010.6282187CS
156-8.97-6014.9518.733.2154660509.11624837CS
260-20.14-77.105666156226.1254.20813.21403448212.82225512CS

IOVA - Frequently Asked Questions (FAQ)

What is the current Iovance Biotherapeutics share price?
The current share price of Iovance Biotherapeutics is US$ 5,98
How many Iovance Biotherapeutics shares are in issue?
Iovance Biotherapeutics has 304 780 790 shares in issue
What is the market cap of Iovance Biotherapeutics?
The market capitalisation of Iovance Biotherapeutics is USD 1,95B
What is the 1 year trading range for Iovance Biotherapeutics share price?
Iovance Biotherapeutics has traded in the range of US$ 5,91 to US$ 18,33 during the past year
What is the PE ratio of Iovance Biotherapeutics?
The price to earnings ratio of Iovance Biotherapeutics is -4,1
What is the cash to sales ratio of Iovance Biotherapeutics?
The cash to sales ratio of Iovance Biotherapeutics is 1,53k
What is the reporting currency for Iovance Biotherapeutics?
Iovance Biotherapeutics reports financial results in USD
What is the latest annual turnover for Iovance Biotherapeutics?
The latest annual turnover of Iovance Biotherapeutics is USD 1,19M
What is the latest annual profit for Iovance Biotherapeutics?
The latest annual profit of Iovance Biotherapeutics is USD -444,04M
What is the registered address of Iovance Biotherapeutics?
The registered address for Iovance Biotherapeutics is 2140 S DUPONT HWY, CAMDEN, DELAWARE, 19934
What is the Iovance Biotherapeutics website address?
The website address for Iovance Biotherapeutics is www.iovance.com
Which industry sector does Iovance Biotherapeutics operate in?
Iovance Biotherapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PHIOPhio Pharmaceuticals Corporation
US$ 7,50
(343,79%)
252,51M
SLRXSalarius Pharmaceuticals Inc
US$ 4,0624
(159,58%)
109,4M
XXII22nd Century Group Inc
US$ 10,26
(109,82%)
19,24M
ATPCAgape ATP Corporation
US$ 2,09
(65,87%)
79,98M
VRMEVerifyMe Inc
US$ 4,19
(64,31%)
51,65M
EHGOEshallgo Inc
US$ 1,2399
(-62,08%)
4,61M
CMTLComtech Telecommunications Corporation
US$ 2,28
(-44,79%)
3,6M
BOWNBowen Acquisition Corporation
US$ 6,25
(-42,71%)
24,58k
LAESSEALSQ Corporation
US$ 3,45
(-39,79%)
62,06M
SVMHSRIVARU Holding Ltd
US$ 0,0381
(-38,35%)
145,48M
GCTKGlucoTrack Inc
US$ 0,142
(21,37%)
628,57M
PHIOPhio Pharmaceuticals Corporation
US$ 7,50
(343,79%)
252,51M
BHATBlue Hat Interactive Entertainment Technology
US$ 0,0649
(-26,33%)
167,86M
SVMHSRIVARU Holding Ltd
US$ 0,0381
(-38,35%)
145,48M
NVDANVIDIA Corporation
US$ 132,0891
(-2,81%)
144,51M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
IOVA
Iovance Biotherapeutics
USOTC
MHIFF
Mineral Hill Industries (PK)
BIT
UC5F0S
Unicredit Bank
BIT
Q00535
Leonteq Securities
BIT
F36015
Vontobel Financial Produ...
BIT
MCHT
Ivz Msci China Tech All ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés